Header Logo

Connection

Jeffrey Kordower to Humans

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Humans.
Jeffrey Kordower
Connection Strength
2.574
Humans
  1. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.047
  2. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.045
  3. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.043
  4. The Unbearable Lightness of Brundin. J Parkinsons Dis. 2022; 12(4):1069-1072.
    View in: PubMed
    Score: 0.042
  5. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.040
  6. Reply to: "Cell Therapy for Huntington's Disease: Learning from Failure". Mov Disord. 2021 03; 36(3):788-789.
    View in: PubMed
    Score: 0.040
  7. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.039
  8. Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
    View in: PubMed
    Score: 0.039
  9. Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
    View in: PubMed
    Score: 0.039
  10. A Failed Future. Mov Disord. 2020 08; 35(8):1299-1301.
    View in: PubMed
    Score: 0.038
  11. Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
    View in: PubMed
    Score: 0.038
  12. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.037
  13. Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 12; 132:104587.
    View in: PubMed
    Score: 0.036
  14. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
    View in: PubMed
    Score: 0.036
  15. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.035
  16. Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease. Mov Disord. 2019 09; 34(9):1274-1278.
    View in: PubMed
    Score: 0.035
  17. Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
    View in: PubMed
    Score: 0.035
  18. Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Mov Disord. 2018 05; 33(5):678-683.
    View in: PubMed
    Score: 0.033
  19. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.033
  20. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
    View in: PubMed
    Score: 0.032
  21. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
    View in: PubMed
    Score: 0.032
  22. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.032
  23. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.031
  24. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
    View in: PubMed
    Score: 0.031
  25. Aging and Parkinson's disease: Different sides of the same coin? Mov Disord. 2017 Jul; 32(7):983-990.
    View in: PubMed
    Score: 0.031
  26. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.
    View in: PubMed
    Score: 0.030
  27. Targeting a-Synuclein as a therapy for Parkinson's disease: The battle begins. Mov Disord. 2017 02; 32(2):203-207.
    View in: PubMed
    Score: 0.030
  28. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.030
  29. How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol. 2016 Aug; 29(4):459-66.
    View in: PubMed
    Score: 0.029
  30. Fetal grafts for Parkinson's disease: Decades in the making. Proc Natl Acad Sci U S A. 2016 Jun 07; 113(23):6332-4.
    View in: PubMed
    Score: 0.029
  31. AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
    View in: PubMed
    Score: 0.028
  32. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.028
  33. Trophic factors for Parkinson's disease: To live or let die. Mov Disord. 2015 Nov; 30(13):1715-24.
    View in: PubMed
    Score: 0.028
  34. Parkinson's disease and prion disease: Straining the comparison. Mov Disord. 2015 Nov; 30(13):1727.
    View in: PubMed
    Score: 0.028
  35. The native form of a-Synuclein: Monomer, tetramer, or a combination in equilibrium. Mov Disord. 2015 Dec; 30(14):1870.
    View in: PubMed
    Score: 0.027
  36. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.027
  37. Gene therapy for Parkinson's disease: still a hot topic? Neuropsychopharmacology. 2015 Jan; 40(1):255-6.
    View in: PubMed
    Score: 0.026
  38. Special issue on stem cells. J Comp Neurol. 2014 Aug 15; 522(12):2689-90.
    View in: PubMed
    Score: 0.025
  39. Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer? Ann Neurol. 2014 Jul; 76(1):20-1.
    View in: PubMed
    Score: 0.025
  40. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014 Jul; 29(8):963-6.
    View in: PubMed
    Score: 0.025
  41. The prion hypothesis of Parkinson's disease: this hot topic just got hotter. Mov Disord. 2014 Jul; 29(8):988.
    View in: PubMed
    Score: 0.025
  42. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.025
  43. In memorium: Roy A.E. Bakay, MD. Mov Disord. 2013 Nov; 28(13):1809-10.
    View in: PubMed
    Score: 0.024
  44. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.024
  45. Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):96-109.
    View in: PubMed
    Score: 0.023
  46. Cell therapy for Parkinson's disease: what next? Mov Disord. 2013 Jan; 28(1):110-5.
    View in: PubMed
    Score: 0.023
  47. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis. 2013; 3(4):581-91.
    View in: PubMed
    Score: 0.023
  48. Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis. 2012 Nov; 48(2):151-2.
    View in: PubMed
    Score: 0.022
  49. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.022
  50. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012 May; 27(6):716-9.
    View in: PubMed
    Score: 0.022
  51. Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012; 200:221-41.
    View in: PubMed
    Score: 0.021
  52. Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
    View in: PubMed
    Score: 0.021
  53. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011 Sep 01; 10(6):703-11.
    View in: PubMed
    Score: 0.021
  54. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.021
  55. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.020
  56. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
    View in: PubMed
    Score: 0.020
  57. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.020
  58. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.019
  59. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
    View in: PubMed
    Score: 0.018
  60. Gene therapy for Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S161-73.
    View in: PubMed
    Score: 0.018
  61. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
    View in: PubMed
    Score: 0.018
  62. Are growth factors the answer? Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S176-80.
    View in: PubMed
    Score: 0.018
  63. Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
    View in: PubMed
    Score: 0.018
  64. Animal rights terrorists: what every neuroscientist should know. J Neurosci. 2009 Sep 16; 29(37):11419-20.
    View in: PubMed
    Score: 0.018
  65. Celebrating neural repair. J Comp Neurol. 2009 Jul 01; 515(1):1-3.
    View in: PubMed
    Score: 0.018
  66. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.018
  67. Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? Neuropsychopharmacology. 2009 Jan; 34(1):254.
    View in: PubMed
    Score: 0.017
  68. Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009; 175:201-16.
    View in: PubMed
    Score: 0.017
  69. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.017
  70. Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
    View in: PubMed
    Score: 0.017
  71. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.016
  72. Introduction to the special ASNTR issue. Cell Transplant. 2008; 17(4):361-2.
    View in: PubMed
    Score: 0.016
  73. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
    View in: PubMed
    Score: 0.016
  74. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.016
  75. Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant. 2007; 16(3):301-12.
    View in: PubMed
    Score: 0.015
  76. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.015
  77. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.014
  78. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
    View in: PubMed
    Score: 0.014
  79. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.014
  80. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
    View in: PubMed
    Score: 0.014
  81. Proximity proteomics reveals unique and shared pathological features between multiple system atrophy and Parkinson's disease. Acta Neuropathol Commun. 2025 Mar 23; 13(1):65.
    View in: PubMed
    Score: 0.013
  82. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.013
  83. Primate models of Parkinson's disease. Exp Neurol. 2003 Oct; 183(2):258-62.
    View in: PubMed
    Score: 0.012
  84. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
    View in: PubMed
    Score: 0.011
  85. Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):13972-4.
    View in: PubMed
    Score: 0.011
  86. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.011
  87. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
    View in: PubMed
    Score: 0.011
  88. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery. 2002 Jan; 50(1):137-45; discussion 145-6.
    View in: PubMed
    Score: 0.011
  89. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res. 2002; 138:421-32.
    View in: PubMed
    Score: 0.011
  90. SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues. Cell Rep Methods. 2021 06 21; 1(2).
    View in: PubMed
    Score: 0.010
  91. A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement. 2021 06; 17(6):933-945.
    View in: PubMed
    Score: 0.010
  92. Inflammation in Experimental Models of a-Synucleinopathies. Mov Disord. 2021 01; 36(1):37-49.
    View in: PubMed
    Score: 0.010
  93. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.010
  94. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
    View in: PubMed
    Score: 0.009
  95. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 03 17; 94(11):481-494.
    View in: PubMed
    Score: 0.009
  96. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
    View in: PubMed
    Score: 0.009
  97. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.009
  98. Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? J Parkinsons Dis. 2020; 10(2):405-411.
    View in: PubMed
    Score: 0.009
  99. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
    View in: PubMed
    Score: 0.009
  100. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.009
  101. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019 06; 137(6):981-1001.
    View in: PubMed
    Score: 0.009
  102. Loss of One Engrailed1 Allele Enhances Induced a-Synucleinopathy. J Parkinsons Dis. 2019; 9(2):315-326.
    View in: PubMed
    Score: 0.009
  103. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. 2020 02; 135:104352.
    View in: PubMed
    Score: 0.009
  104. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. 2019 05; 68(5):829-843.
    View in: PubMed
    Score: 0.009
  105. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.008
  106. Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One. 2018; 13(2):e0193438.
    View in: PubMed
    Score: 0.008
  107. Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Mov Disord. 2018 04; 33(4):652-654.
    View in: PubMed
    Score: 0.008
  108. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease. Brain. 2017 Nov 01; 140(11):2982-2992.
    View in: PubMed
    Score: 0.008
  109. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
    View in: PubMed
    Score: 0.008
  110. The Search for a Peripheral Biopsy Indicator of a-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017 01 01; 76(1):2-15.
    View in: PubMed
    Score: 0.007
  111. The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. J Parkinsons Dis. 2017; 7(2):331-346.
    View in: PubMed
    Score: 0.007
  112. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.007
  113. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis. 2016 10 19; 6(4):703-707.
    View in: PubMed
    Score: 0.007
  114. Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. J Parkinsons Dis. 2016 10 19; 6(4):761-770.
    View in: PubMed
    Score: 0.007
  115. Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
    View in: PubMed
    Score: 0.007
  116. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016 Apr 04; 4:35.
    View in: PubMed
    Score: 0.007
  117. Preface. Mov Disord. 2016 Feb; 31(2):151.
    View in: PubMed
    Score: 0.007
  118. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.007
  119. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.007
  120. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.007
  121. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
    View in: PubMed
    Score: 0.007
  122. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr; 254:90-8.
    View in: PubMed
    Score: 0.006
  123. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
    View in: PubMed
    Score: 0.006
  124. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
    View in: PubMed
    Score: 0.005
  125. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 06; 480(7378):547-51.
    View in: PubMed
    Score: 0.005
  126. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.005
  127. ?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
    View in: PubMed
    Score: 0.005
  128. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.005
  129. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem. 2010 Jun; 113(5):1073-91.
    View in: PubMed
    Score: 0.005
  130. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov; 66(5):591-6.
    View in: PubMed
    Score: 0.005
  131. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A. 2009 Jul 28; 106(30):12483-8.
    View in: PubMed
    Score: 0.004
  132. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
    View in: PubMed
    Score: 0.004
  133. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.004
  134. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.004
  135. Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
    View in: PubMed
    Score: 0.004
  136. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.004
  137. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
    View in: PubMed
    Score: 0.004
  138. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.004
  139. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
    View in: PubMed
    Score: 0.004
  140. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.004
  141. Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg. 2006 Jul; 105(1):96-102.
    View in: PubMed
    Score: 0.004
  142. Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006 Jan; 59(1):166-73.
    View in: PubMed
    Score: 0.003
  143. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 May; 11(5):551-5.
    View in: PubMed
    Score: 0.003
  144. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004 Sep; 33(5):517-33.
    View in: PubMed
    Score: 0.003
  145. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003 Sep; 4(9):727-38.
    View in: PubMed
    Score: 0.003
  146. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.003
  147. Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol. 2003 Aug 25; 463(3):341-57.
    View in: PubMed
    Score: 0.003
  148. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb; 51(2):145-55.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.